HC Wainwright Reiterates Buy Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $123.00 price objective on the biotechnology company’s stock, up from their previous price objective of $117.00. HC Wainwright’s price target points to a potential upside of 288.50% from the company’s previous close.

Separately, StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th.

XOMA Trading Down 2.4 %

Shares of NASDAQ XOMA opened at $31.66 on Monday. The stock’s 50 day moving average price is $29.57 and its two-hundred day moving average price is $27.46. XOMA has a 52-week low of $14.77 and a 52-week high of $35.00. The stock has a market capitalization of $372.95 million, a P/E ratio of -9.10 and a beta of 0.88. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Buying and Selling at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On XOMA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ellsworth Advisors LLC acquired a new stake in shares of XOMA during the 3rd quarter valued at $516,000. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA in the first quarter valued at $212,000. Bank of New York Mellon Corp lifted its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.